STAMPEDE group to present abiraterone survival data at ASCO too

We have just heard from the STAMPEDE trial group in the UK that they will be presenting overall survival data from the “abiraterone comparison” arm of the STAMPEDE trial at the upcoming ASCO meeting this year. … READ MORE …

Aggressive, neoadjuvant androgen ablation prior to surgery in higher risk prostate cancer patients

The development of drugs like abiraterone acetate and enzalutamide has stimulated new research into the use of such agents early on, in combination with first-line therapy, to see if it can affect the outcomes for men with high-risk and unfavorable intermediate-risk prostate cancer. … READ MORE …

No sign of evident clinical benefit in the Phase IV PLATO trial

According to a recent media release, there was no significant benefit for the investigational combination of enzalutamide (Xtandi) + abiraterone acetate (Zytiga) + prednisone in treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (cnmCRPC). … READ MORE …

Non-rising PSA but radiographic progression in men on treatment with enzalutamide

A recent presentation at the European Society of Medical Oncology (ESMO) annual meeting in Copenhagen, Denmark, has suggested that some men on treatment with enzalutamide (Xtandi) may have radiographic progression of their cancer even though there is no increase in their PSA levels. … READ MORE …

Pfizer completes acquisition of Medivation

As of midnight last night, Pfizer completed the acquisition of Medivation and therefore enzalutamide (Xtandi) is now being sold in the USA by Pfizer and Astellas and by Astellas in the rest of the world. For the details, see here.

Pfizer to buy Medivation (developer of Xtandi)

According to news this morning, Pfizer has entered into a merger agreement which will allow the company to buy Medivation (the developer of enzalutamide, also known as Xtandi). Rumors had been rife since last Friday. … READ MORE …

The price — and the politics — of drug therapy for advanced prostate cancer

According to a story on the MarketWatch web site yesterday, two not-for-profit organizations have been seeking hearings on revocation of patents held by Medivation on the drug enzalutamide (Xtandi). … READ MORE …